Angle Plc Surrey Stock Price, News & Analysis

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced new share option grants under its Long-Term Incentive Plan (LTIP) and staff share option plans. The company approved 12 million LTIP Options for executive directors and up to 13.8 million Staff Share Options.

The allocation considers that no bonuses were awarded for three consecutive years to conserve cash. The Staff Share Options are priced at 10.00 pence per share, 2.6% above the closing price of 9.75 pence on March 20, 2025. Following these grants, ANGLE will have outstanding options over 51,369,480 Ordinary Shares, representing 13.7% of issued capital, within the approved 16% limit.

The LTIP Options include a three-year performance period plus a two-year holding period, with performance conditions linked to share price CAGR above the June 2024 funding round price of 15.00 pence per share.

ANGLE plc (ANPCY) has announced successful completion of key development projects with AstraZeneca and Eisai. The company has developed two assays for AstraZeneca: a prostate cancer androgen receptor (AR) assay and a multi-cancer DDR micronuclei assay for DNA damage detection in CTCs.

The AR therapeutic market is projected to reach $9.2 billion by 2033, with over 46,000 patients in 181 clinical studies. The DDR therapeutic market, valued at $8.2 billion in 2024, is expected to grow to $30.3 billion in the next decade.

Additionally, ANGLE's Parsortix-based HER2 assay demonstrated successful results in Eisai's Phase 2 pilot study for breast cancer patients, showing the ability to measure HER2 status changes over time. The HER2 therapeutic market, valued at $9.4 billion in 2023, is projected to reach $13.2 billion by 2030.

ANGLE plc has announced breakthrough research from ETH Zurich published in Nature Medicine, featuring their Parsortix system in a Phase 1 clinical trial for metastatic breast cancer treatment. The study used FDA-approved drug digoxin and demonstrated the Parsortix system's critical role in identifying patients with CTC clusters for targeted treatment.

The trial achieved its primary endpoint, showing significant reduction in CTC cluster size in the treatment group. This proof-of-principle study opens possibilities for developing novel drugs preventing metastasis. Professor Aceto's lab has co-founded PAGE Therapeutics to develop compounds effective at disassociating CTC clusters, with Parsortix expected to play a important role in future development.

The research is particularly significant as metastasis accounts for the majority of cancer-related deaths. The Parsortix system's unique ability to capture CTC clusters makes it valuable for developing drugs targeting metastatic spread, potentially improving patient outcomes across all solid tumors.

ANGLE plc announced the presentation of an independent study by Weill Cornell Medicine at the San Antonio Breast Cancer Symposium, showcasing a novel Parsortix-based HER2 workflow. The study, involving 16 metastatic breast cancer patients, demonstrated 100% success in isolating CTCs and classifying their HER2 status. The research identified patients with HER2-expressing CTCs who had HER2-negative tissue biopsies, suggesting potential for expanded treatment options.

The workflow enables quantitative and semi-automated assessment of HER2 in CTCs, which is important as HER2 status can change in up to 38% of breast cancer patients. This development could help identify patients eligible for HER2-targeted antibody drug conjugates (ADCs), particularly beneficial for the over 60% of breast cancer patients initially diagnosed as HER2-negative.

ANGLE plc has presented new data at the AACR Special Conference showcasing their Parsortix-based PD-L1 assay for lung cancer monitoring. The assay demonstrated high analytical sensitivity and specificity in identifying different CTC phenotypes and determining PD-L1 status. In a study of metastatic lung cancer patients, CTCs were identified in 91% of cases, with PD-L1 positive CTCs found in 72% of patients with PD-L1 positive tissue biopsies and 27% of those with negative biopsies. The technology enables minimally invasive, longitudinal monitoring of PD-L1 status, potentially advancing personalized treatment approaches.

ANGLE plc presented two posters at the EACR Liquid Biopsies Conference in Lyon, France. The first poster demonstrated the effectiveness of combining Parsortix system with Portrait+ CTC staining kit for detecting and characterizing circulating tumor cells (CTCs). In prostate cancer patients, 64% showed CTC positivity, with 67% of positive samples containing CTC clusters. Notably, 77% of CTC-positive patients had only mesenchymal CTCs.

The second poster showcased enhanced multiplexing capabilities in digital PCR for CTC analysis, demonstrating improved molecular characterization potential using QIAGEN's Qiacuity dPCR system with Parsortix-enriched samples. This advancement allows for simultaneous assessment of multiple genes from a single sample.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with NuProbe USA, Inc. for the use of their proprietary pan-cancer next generation sequencing (NGS) panel. The agreement grants ANGLE an option for an exclusive global license to the NGS panel outside of China for analyzing circulating tumor cells (CTCs) and dual analysis of CTCs and circulating tumor DNA (ctDNA).

The NGS panel enables highly sensitive detection of over 6,500 DNA mutations in 61 clinically relevant genes. It has been validated on the Illumina sequencer and aligns with key drug targets under development by large pharma. This agreement aims to accelerate ANGLE's commercialization of its first pan-cancer molecular sequencing assay, with immediate applicability to pharma services customers and translational researchers using the Parsortix® system.

A pilot study conducted by ANGLE demonstrated that more mutations were identified exclusively in CTCs compared to ctDNA alone in breast, lung, and ovarian cancer patients, highlighting the potential value of profiling CTCs in addition to ctDNA.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with Recursion Pharmaceuticals for a pilot study using ANGLE's Parsortix CTC analysis. The study is fully funded, with potential for larger follow-on contracts if successful. This marks ANGLE's fourth pharma agreement in 2024, expanding its large pharma services business. Recursion, a clinical-stage TechBio company, has partnerships with multiple leading large pharma companies. While the initial study is modest in size, it could lead to significant opportunities. The agreement's details remain confidential between the parties.

ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the release of its interim results for the six months ended 30 June 2024. The results will be published on Thursday 26 September 2024.

An analyst meeting is scheduled for 11:00 am BST on the same day at Berenberg's offices in London. A live webcast of the meeting will be accessible through ANGLE's Investor Centre page, with Q&A participation reserved for analysts. The webcast recording will be made available on ANGLE's website following the event.